291 related articles for article (PubMed ID: 27086286)
1. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL).
Hershman DL; Kushi LH; Hillyer GC; Coromilas E; Buono D; Lamerato L; Bovbjerg DH; Mandelblatt JS; Tsai WY; Zhong X; Jacobson JS; Wright JD; Neugut AI
Breast Cancer Res Treat; 2016 May; 157(1):133-43. PubMed ID: 27086286
[TBL] [Abstract][Full Text] [Related]
2. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
3. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
Salgado TM; Davis EJ; Farris KB; Fawaz S; Batra P; Henry NL
Breast Cancer Res Treat; 2017 Jun; 163(2):311-319. PubMed ID: 28251384
[TBL] [Abstract][Full Text] [Related]
4. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer.
Nekhlyudov L; Li L; Ross-Degnan D; Wagner AK
Breast Cancer Res Treat; 2011 Nov; 130(2):681-9. PubMed ID: 21842245
[TBL] [Abstract][Full Text] [Related]
5. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
[TBL] [Abstract][Full Text] [Related]
6. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
[TBL] [Abstract][Full Text] [Related]
7. Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer.
Walker HE; Rosenberg SM; Stanton AL; Petrie KJ; Partridge AH
J Adolesc Young Adult Oncol; 2016 Mar; 5(1):16-23. PubMed ID: 26812461
[TBL] [Abstract][Full Text] [Related]
8. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
9. Adherence to adjuvant endocrine therapy in women with breast cancer.
Danilak M; Chambers CR
J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.
Kesmodel SB; Goloubeva OG; Rosenblatt PY; Heiss B; Bellavance EC; Chumsri S; Bao T; Thompson J; Nightingale G; Tait NS; Nichols EM; Feigenberg SJ; Tkaczuk KH
Am J Clin Oncol; 2018 May; 41(5):508-512. PubMed ID: 27322700
[TBL] [Abstract][Full Text] [Related]
11. Persistence to 5-year hormonal breast cancer therapy: a French national population-based study.
Bosco-Lévy P; Jové J; Robinson P; Moore N; Fourrier-Réglat A; Bezin J
Br J Cancer; 2016 Oct; 115(8):912-919. PubMed ID: 27599040
[TBL] [Abstract][Full Text] [Related]
12. Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I-III breast cancer?
Cahir C; Barron TI; Sharp L; Bennett K
Cancer Causes Control; 2017 Mar; 28(3):215-225. PubMed ID: 28210883
[TBL] [Abstract][Full Text] [Related]
13. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
[TBL] [Abstract][Full Text] [Related]
14. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey.
Xu H; Jin F; Zhang XJ; Wang DQ; Yu SF; Wang AP
Cancer Med; 2020 Jun; 9(11):3703-3713. PubMed ID: 32237070
[TBL] [Abstract][Full Text] [Related]
15. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
[TBL] [Abstract][Full Text] [Related]
16. Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence.
Hurtado-de-Mendoza A; Jensen RE; Jennings Y; Sheppard VB
J Cancer Educ; 2018 Apr; 33(2):436-439. PubMed ID: 28205022
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
[TBL] [Abstract][Full Text] [Related]
18. Compliance and persistence of endocrine adjuvant breast cancer therapy.
Güth U; Myrick ME; Kilic N; Eppenberger-Castori S; Schmid SM
Breast Cancer Res Treat; 2012 Jan; 131(2):491-9. PubMed ID: 21976056
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.
Rosenberg SM; Zheng Y; Gelber S; Ruddy KJ; Poorvu P; Sella T; Tamimi RM; Wassermann J; Schapira L; Borges VF; Come S; Peppercorn J; Sepucha KR; Partridge AH
Breast Cancer Res Treat; 2023 Feb; 197(3):547-558. PubMed ID: 36436128
[TBL] [Abstract][Full Text] [Related]
20. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.
Hadji P
Crit Rev Oncol Hematol; 2010 Feb; 73(2):156-66. PubMed ID: 19299162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]